Uncontrolled bleeding and possible death. Pradaxa. This drug came onto the market in October 2010. It was designed to be the best blood thinning medication on the market for prevention of blood clots following certain medical procedures.
Older blood thinning medications such as warfarin or coumadin require consistent monitoring of the clotting factor of a patient’s blood and adjustment in the dosage of the medication depending on the test results. The pharmaceutical company Boehringer Ingelheim, maker of Pradaxa, specifically claims that the drug’s greatest benefit is that no monitoring is necessary for its use.
Problem? There isn’t any antidote to reverse Pradaxa’s effects. It thins the blood, but if a patient starts bleeding it can quickly become uncontrollable and can lead to death. In 2011 the FDA showed that 542 deaths and 3,781 side effect incidents related to Pradaxa were reported.
Because there have been so many adverse events reported to the FDA over such a short period of time, it’s certainly in question if the manufacturer, Boehringer Ingelheim, acted responsibly and appropriately when developing this medication. Of particular concern is the fact that this medication hit the market without any way of counteracting its blood thinning effects.
Individuals and families who have been hurt by Pradaxa have filed lawsuits against Boehringer Inglheim. The number of cases filed is steadily increasing. If you or someone you care about has been hurt or died as a result of Pradaxa, contact us immediately.